The Prescription Patterns and Clinical Efficacy of Tenero Tab/Tenero M SR Tab

Observational Study on the Prescription Patterns and Clinical Efficacy of Tenero Tab/Tenero M SR Tab in Korean Type 2 Diabetes Mellitus Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06188234

Enrollment

3000

Registered

2024-01-03

Start date

2022-12-27

Completion date

2026-06-30

Last updated

2024-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Metformin HCI, Teneligliptin hydrochloride

Brief summary

This study is to observe the prescription patterns and clinical efficacy of patients prescribed with Tenero Tab/Tenero M SR Tab for diabetes treatment in routine clinical practice.

Detailed description

This study is to observe the clinical efficacy by analyzing the prescription patterns in routine clinical practice and changes in HbA1c, FPG, PP2G, etc., of patients prescribed with Tenero Tab/Tenero M SR Tab for diabetes treatment. Additionally, the study intends to assess patient satisfaction based on these observations.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Inclusion criteria

1. Adults over 19 years of age 2. Individuals diagnosed with type 2 diabetes. 3. Individuals who, at the clinical discretion, are prescribed Tenero Tab or Tenero M SR Tab for the purpose of diabetes treatment for the first time. 4. Individuals who have voluntarily provided written consent to participate in this study.

Exclusion criteria

1. Pregnant or breastfeeding women. 2. Individuals who are contraindicated according to the approved indications of Tenero Tab/Tenero M SR Tab. 3. Other cases where the principal investigator and study personnel deem individuals ineligible for participation in this clinical trial.

Design outcomes

Primary

Measure	Time frame	Description
Change in HbA1c at 6 months of prescribing Tenero Tablet/Tenero Emextended Release Tablet compared to baseline	after 6 months of prescription for Tenero Tab/Tenero M SR Tab compared to baseline	Change in HbA1c at 6 months of prescribing Tenero Tablet/Tenero Emextended Release Tablet compared to baseline

Countries

South Korea

Contacts

Primary ContactYeonhwa Kim

yh@hanlim.com82-2-3489-6163

Outcome results